TG Therapeutics TGTX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's long-term debt?
- TG Therapeutics (TGTX) reported long-term debt of $745.14M in Q1 2026.
- How has TG Therapeutics's long-term debt changed year-over-year?
- TG Therapeutics's long-term debt increased by 204.5% year-over-year, from $244.73M to $745.14M.
- What is the long-term trend for TG Therapeutics's long-term debt?
- Over 5 years (2020 to 2025), TG Therapeutics's long-term debt has grown at a 99.8% compound annual growth rate (CAGR), from $7.72M to $245.65M.
- What does long-term debt mean?
- Debt that is not due for payment within the next year.
- How do you interpret long-term debt?
- While debt can fuel growth, excessive long-term debt increases financial risk and interest burdens, potentially impacting future profitability.
- How does long-term debt compare across companies?
- Biotech companies often carry varying levels of debt depending on their stage of development and access to equity markets.